Work

128P Comparative efficacy and safety of first-line maintenance therapies in advanced ovarian cancer: A biomarker-stratified Bayesian network meta-analysis of 16 phase III trials

Year: 2026

Type: review

Study designs: Systematic Review, Meta-Analysis

Abstract: The integration of poly(ADP-ribose) polymerase inhibitors (PARPi), immune checkpoint inhibitors, and anti-angiogenics has transformed first-line maintenance for advanced ovarian cancer (AOC), yet optimal regimens across biomarker profiles remain undefined. Aim is To evaluate the comparative efficacy and safety of frontline maintenance therapies across homologous recombination deficiency (HRD) and BRCA mutation (BRCAm) profiles in AOC.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.108175

Authors: R. Falodia, S. Sequeira

Institutions: All India Institute of Medical Sciences Jodhpur, King Edward Memorial Hospital and Seth G.S. Medical College

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910